A World of Biomanufacturing: Shortages or Global Glut?
|
|
- Augustine Holland
- 8 years ago
- Views:
Transcription
1 A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010
2 Steady growth in the number of biopharmaceutical products No. Products EU Non-MAbs EU MAbs US Non-MAbs US MAbs 20 0 Pre Number of approved products in the US has steadily increased from approximately 20 in 1995 to 114 today Graph includes products approved but later withdrawn from market and produced via both mammalian cell culture and microbial fermentation Data includes 89 products approved by EMEA Data does not include all products approved by EU member states before centralized procedures were adopted Year
3 Coupled with continued growth of product sales 2009 US sales for 130 biologic products exceeded $95 billion 11% of total pharmaceutical market 16% annual growth rate In 2009, 27 biopharmaceutical 18 products with worldwide sales 12 in excess of $1 Billion 6 1 fewer blockbuster product than in manufactured by microbial fermentation Mammalian Recombinant Products Microbial Recombinant Products 17 manufactured by mammalian cell culture 9 antibody based products, including full length antibodies, antibody fragments, and Fc fusion proteins A n n ual Sal es ($ B ) Mammalian MAb Products Microbial MAb Products
4 Leads to growing demand for biopharmaceutical manufacturing Cell Culture Recombinant Proteins Microbial Fermentation 12, Cell Culture Microbial Fermentation 7,599 Approximately 13 metric tons of product manufactured by microbial fermentation 63% of total annual protein production Insulin accounts for >90% of this production 6 kg of monoclonal antibody products Approximately 7.5 metric tons produced in mammalian cell culture 7,599 kg monoclonal antibody products 111 kg recombinant proteins Monoclonal Antibody Products 6
5 With demand for biopharmaceutical products continuing kg Required (kg/yr) 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 - Pipeline Clinical Commercial Most probable demand for all products currently on the market or in development Green arrow denotes anticipated demand if all five top drivers currently in development succeed Red arrow denotes anticipated demand if all five top drivers currently in development fail
6 Monoclonal antibody products represent the fastest growing segment of the pharmaceutical industry Mammalian Microbial Other (Plant, Insect, etc.) No. Products Market BLA/NDA Phase 3 Phase 2 Phase 1** Approximately 65% of all biopharmaceutical products in development are monoclonal antibody related products Approximately 85% of mammalian cell culture products and 25% of microbial fermentation products are monoclonal antibody related products
7 Estimated demand for the top six monoclonal antibody products exceeds 80% of total demand for all mammalian cell culture products Bulk Requirem ents 2009 (Kg) 1,600 1, ,331 1,255 1,229 1, ,427 0 Remicade Rituxan Avastin Enbrel Herceptin Erbitux All Other Products (68)
8 Demand for mammalian cell culture continues Currently 57% of all commercial biopharmaceutical products and approximately 65% of all products in development produced in mammalian cell culture Does the industry have enough capacity to meet this demand? What will manufacturing operations look like in 2015?
9 In the late 1990 s and early 2000 s, companies struggled to obtain needed biopharmaceutical manufacturing capacity and extreme capacity shortages were forecasted We estimate that capacity will more than a triple by Unfortunately, we estimate that demand for capacity will quadruple over this time period - JP Morgan report (2002)
10 Despite the announcement of investments in significant amounts of additional capacity, shortages were still projected by some Current projections point to a serious shortfall developing within three years in manufacturing capacity, especially in mammalian cell culture... - DM&D Report (2003)
11 However, projections showed low probability of shortages Ref: Levine HL. The capacity crunch reality or myth? Presented at IBC Production Economics and Manufacturing Strategies of Biologicals; 2003 Jun 16 17; Brussels, Belgium 4,000 Reactor Volume ('000 L) 3,500 3,000 2,500 2,000 1,500 1, Year Forecast Industry-wide Capacity Most Probable Case Capacity utilization increases to almost 100% by 2010 Top 5 Potential Volume Drivers Fail Capacity utilization drops to <55% through 2007 Top 5 Potential Volume Drivers Succeed Approximately 10% capacity shortage by 2007
12 By 2009 capacity shortages still have not materialized... Increases in product titers and operational excellence initiatives have improved overall productivity BioProcess Technology Consultants report, Published December 2008 Sufficient capacity worldwide to meet current annual production needs with a high probability of sufficient capacity for the foreseeable future
13 Nevertheless, some still predicting capacity constrains Nearly one-half of survey respondents predicted that their manufacturing facilities would experience capacity constraints by BioPlan Associates report (2010)
14 So where do we really stand? An optimist will tell you the glass is half full; the pessimist, half empty; and the engineer will tell you the glass is twice the size it needs to be anonymous
15 Abundant cell culture capacity worldwide Installed Capacity (,000L) 2,000 1,750 1,500 1,250 1, Asia Europe North America Data from 101 companies in 28 countries worldwide indicates an increase in capacity from approximately 2.5 million liters in 2009 to approximately 4 million liters in 2015 Capacity growth will be greater in Asia than in EU or North America Year Recent economic downturn resulted in slowing of projected capacity expansion plans Ref: E. Reynolds, PhD Dissertation, MIT (2010)
16 However 10 companies control 80% of worldwide capacity decreasing slightly to 73% by % By 2015, Genzyme replaced by Celltrion in top 10 25% 20% 15% 10% 5% 0% A B C D E F G H I J K L A. Roche B. Amgen C. Pfizer D. Boehringer Ingelheim E. J&J/Centocor F. Lilly G. Lonza H. Novartis I. Biogen Idec J. Genzyme K. Celltrion L. All Others
17 Balance of worldwide cell culture capacity between product companies and CMOs favors product companies Est. Installed Reactor Volume (KL) 4,200 3,600 Product Co. Both 3,000 CMO 2,400 1,800 1, Year Product companies currently control approximately 70% of total capacity, decreasing slightly by 2015
18 Overall balance of cell culture capacity supply and demand Installed Capacity (,000L) 4,200 3,600 3,000 2,400 1,800 1, Available Supply Pipeline Clinical Commercial Most Probable Demand Drivers Pass Drivers Fail Total facility utilization was 41% in 2009 increasing to a projected most probable utilization of 68% by 2015 Variable capacity utilization and uneven distribution of capacity means that several large facilities currently have available capacity Impact of pipeline volume drivers on overall facility utilization If all succeed, utilization increases to 77% If all fail, utilization decreases to 61%
19 Impact of today s overcapacity on outsourcing Outsourcing remains an option for many companies with greater choices now available as product companies with excess capacity offer this captive capacity for contract manufacturing You can now leverage our clinical contract manufacturing capabilities for your therapeutics... - Amgen BIO conference (2010) CMOs are more flexible today in pricing and schedule and Sponsors are demanding better service and more attention than before Increased capacity utilization in the CMO market as a result of consolidation among this group and slowdown of expansion
20 Trends That Will Impact Future Capacity Utilization Success or failure of a limited number of high volume products currently in late stage clinical development Acquisition of volume driver product candidates by product companies having significant capacity may free up CMO capacity Fewer blockbuster drugs with greater focus on smaller markets and niche products Mergers and acquisitions, resulting in redundant facilities in larger organizations (i.e., the rich get richer) Companies are moth balling or not starting up facilities due to excess capacity
21 Continued innovation has increased expression levels and yields 1978 Recombinant insulin produced Commercial products have expression levels in the range 2006 of g/l with the highest titers seen for monoclonal antibody products Industry Standard: 1-2 g/l Industry Leaders: 3-6 g/l Improved strains New technologies to improve cell line development and expression levels coupled with improved and optimized media, supplements, and bioreactor conditions have increased titers of products in development Future Leaders: >10 g/l Ref: T. Charlebois, BIOMAN 2006 Conference, (2006); M. Smith, BPI Europe Conference (2005); F. Wurm, Nature Biotechnology, 22(11) (2004)
22 Effect of titer on demand for manufacturing capacity over time Two fold increase in industry wide productivity will reduce overall capacity requirements approximately 25% by ,000 Total Volume Requirements (,000L) 3,500 3,000 2,500 2,000 1,500 1, Year x 1x Titer Increase 1.5x 2x 2007 Higher titers and lower doses will reduce capacity demand for future commercial products
23 Personalized medicine initiatives will transform medicine and influence scale and demand for manufacturing capacity Targeted Therapy Rational drugs based on profiling of underlying molecular pathology Individualized Therapy Rational drugs based on comprehensive molecular profiling of individuals Personalized Care Integrated data on individual health status Transition to disease prediction and preemption Graphic adapted from: S. Burrill, IBC Development and Production (2010) Greater focus on smaller markets and niche products will result in fewer blockbuster drugs and a decrease in capacity demands for individual products
24 Better diagnostics will reduce waste in heathcare spending drive the development of targeted therapies Ref: S. Burrill, IBC Development and Production (2010)
25 Today s Biopharmaceutical Facility Most facilities today were built for low titer (<1 g/l) processes Multiple 20,000 L bioreactors each with inoculum bioreactors up to 4,000 L Current facilities struggle to match downstream capacity with bioreactor output due to large process volumes Technologies that enable higher bioreactor titers will exaggerate the DSP bottleneck Photos courtesy of Lonza Biologics
26 Producing 10 Metric Tons of Monoclonal Antibody But do we really need this much? Ref: B. Kelley, ACS Conference, (2006)
27 How much product do we need? Demand for all existing commercial monoclonal antibody products will approximately double from the current 7.7 metric tons to approximately 15.9 metric tons by 2015 Current annual product requirements for each of the top five monoclonal antibody products ranges from 941 kg to 1,331 kg Demand for products currently in development will increase the future demand for cell culture manufacturing capacity even further The anticipated demand for any new monoclonal antibody products approved between now and 2015 is expected to be less than 5 metric tons per year
28 The biopharmaceutical manufacturing facility of the future will Incorporate high titer (>10 g/l) processes Use disposable technologies to reduce capital investment and operating costs Anticipated reduction of over 50% (J. Roebers, BPI [2009]) Require greater DSP space and capabilities to better handle the high titer bioreactor output Ratio of bioreactor space to DSP space will decrease Use smaller bioreactors to produce similar quantities to today s larger bioreactors Reduced capital requirements may enable smaller companies to construct their own facilities rather than outsource
29 Single use and disposable technology will change the look and feel of future manufacturing facilities Increased facility utilization by reducing change over time Reduced fixed piping Reducing cleaning and validation costs in multiproduct operations Increased operational flexibility by minimizing or eliminating multi use equipment Improved process portability and ability to manage and implement process changes Photo courtesy of Acceleron Pharma
30 Approaches to debottlenecking downstream processing Use of negative chromatography as an alternative to a dedicated capture step High product titers enables capture of impurities while product flows through column Process bioreactor harvest in multiple batches Clarify and freeze bioreactor harvest for purification in smaller batches Use of disruptive technologies such as precipitation, expanded bed, and simulated moving bed chromatography Ref: A. DePlama GEN (2010 May 1)
31 Continuous purification with simulated moving bed chromatography is extremely scaleable and leads to substantial reduction in manufacturing costs Fully disposable processing train can be paired with disposable bioreactors resulting in smaller process footprint Higher throughput per square foot of manufacturing space enables high titer processes to fit in existing facilities v Wash Elution Wash Photos courtesy of BioFlash
32 Continuous disposable downstream processing with BioSMB Process uses same fundamental phenomena as batch processes No change in media and buffer composition Same steps for binding, washing, and elution as in the corresponding batch process System volume depends on mass transfer kinetics, not binding capacity or titer Batch BioSMB Titer 3.5 gm/l Batch size 2000 L Productivity [g/l/day] Processing time 05:10 08:00 12:00 24:00 Protein A media [L] Buffer [L] Number of columns Cycles per batch Protein A Media Costs $ 880k $ 80k $ 52k $ 26k Data courtesy of Tarpon Biosystems
33 BioSMB makes size exclusion chromatography fun again UV 280 in product [AU] Cycle 3 Cycle 4 Cycle Time [min] - Each column switch = 10 min Continuous gel filtration chromatography of a vaccine VLP using a 12 column process set up Photos and data courtesy of Tarpon Biosystems
34 Future biomanufacturing facilities will need to balance multiple factors to meet performance and productivity goals Capacity Variety of product types with differing manufacturing processes Flexibility Scalability Performance/ Productivity Quality/ Regulatory Speed Antibodies, antibody fragments, fusion protein, recombinant proteins Cell culture vs microbial fermentation Low titer vs high titer Cost No one facility will fit all products or processes
35 Diversity of manufacturing facilities in the future Low volume, low titer products (<20 Kg/year) Little to no reason for process changes for existing products New low titer products (primarily non MAb products) will emerge Large manufacturing plants designed for multiproduct operation High volume, high titer products (>100 Kg/year) Antibodies will be drivers for platforms and very low COGS Increased use of disposable technology will reduce capital costs Dedicated plants with appropriately sized (i.e., smaller) bioreactors Adapted from W. Berthold, BPI Asia Conference (2008)
36 The biomanufacturing facility of the future Plant has 6 x 2,000 L bioreactors (possibly disposable reactors) 12 day fed batch CHO culture 2,000 volume, 15 g/l = 30 kg in harvest 80% purification yield = 24 kg per batch Harvest every 2 days 167 harvests (334 days) = 4 tons/year 1 Purification train serving single bioreactor Estimated facility cost <$100M Estimated COGS $70 per gram Photos courtesy of Xcellerex
37 Summary Sufficient capacity worldwide to meet annual production needs for the foreseeable future Uneven distribution of capacity may present difficulties to some companies trying to access capacity
38 Summary Fewer blockbuster drugs and greater focus on smaller, niche products with smaller commercial demands implies: Less difference in scale between pilot and commercial facilities Use of multipurpose plants with potential for continuous production
39 Summary Product and process innovations resulting in higher yields per batch and lower demand for bioreactor capacity implies: Investments in manufacturing facilities will continue to slow Increased use of disposables rather than steel in facilities Disposable/single use technologies possible for some commercial supply
40 Special thanks to Dawn Ecker BPTC database manager Data collection and analysis Companies providing data and pictures Acceleron Pharma BioFlash (Repligen) Lonza Biologics Tarpon Biosystems Xcellerex
41 We re moving As of June 15, 2010: BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA and web remain the same:
42 THANK YOU!
Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals
Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals Howard L. Levine and Susan Dana Jones BPI Europe 2013 Apr 17-18, 2013 Dusseldorf, Germany BioProcess Technology Consultants
More informationChallenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies
Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com
More informationOne of the greatest challenges facing biopharmaceutical
Monoclonal Antibody Manufacturing Strategies for the 21st Century James Blackwell, Ph.D., MBA Sr. Consultant Thomas Ransohoff, VP and Sr. Consultant Howard L. Levine, Ph.D., President and Principal Consultant
More informationVaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010
Vaccine Manufacturing Facilities of the Future Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Challenges in the Production of Vaccines Different technology platforms make it
More informationBiomanufacturing Vision for the Future
Biomanufacturing Vision for the Future Shou-Bai Chao, Ph.D. Senior Vice President Global Manufacturing and Technical Operations MedImmune (a Div of AstraZeneca) NIPTE/FDA Research Conference Future of
More informationEden Biodesign ebook Monoclonal Antibody Production: Building the Platform
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign
More informationThe authors: Howard L. Levine, Ph.D., President and Founder. Thomas C. Ransohoff, Senior Consultant
The authors: Howard L. Levine, Ph.D., President and Founder Dr. Levine has over 20 years of experience in the biopharmaceutical industry. Prior to founding BioProcess Technology Consultants to provide
More informationConsiderations Impacting the Make vs. Buy Decision
Considerations Impacting the Make vs. Buy Decision Thomas C. Ransohoff BioProcess Technology Consultants, Inc. INTRODUCTION AND BACKGROUND D ecisions related to manufacturing are among the most important
More informationElisabeth B. Reynolds INDUSTRIAL PERFORMANCE CENTER MASSACHUSETTS INSTITUTE OF TECHNOLOGY WORKING PAPER SERIES MIT-IPC-11-001.
INDUSTRIAL PERFORMANCE CENTER MASSACHUSETTS INSTITUTE OF TECHNOLOGY WORKING PAPER SERIES Elisabeth B. Reynolds MIT-IPC-11-001 March 2011 292 Main Street, E38-104, Cambridge, MA 02139-4307 617-253-7522
More informationTable of Contents. Presented by
Improving Markets, Services, and Technologies Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com
More informationTHOMAS C. RANSOHOFF Vice President and Principal Consultant
THOMAS C. RANSOHOFF Vice President and Principal Consultant +1.781.281.2704 (o) +1.617.759.4109 (m) transohoff@bptc.com Profile An expert in the development and scale up of biopharmaceutical processes;
More informationManufacturing processes for
Single-Use, Continuous- Countercurrent, Multicolumn Chromatography Marc Bisschops, Lynne Frick, Scott Fulton, and Tom Ransohoff Reprinted with permission from BioProcess International 7(6) (June 2009)
More informationRepligen Reports Third Quarter 2015 Financial Results
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2015 Financial Results - Product Sales Increase 31% to $19.8 Million - - Conference
More informationBiopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities
1 Biopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities Presented by Dr. Philipp Hess Supply Chain Management Issues and Opportunities 2 1. How do we
More informationMab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation.
Mab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation. Summary Monoclonal antibodies are expensive to develop and to manufacture.
More informationThe Importance of Developing a High Yield of Product
European Antibody Congress Lyon, 3 rd November 2005 The Importance of Developing a High Yield of Product John Birch, Lonza Biologics plc Monoclonal Antibodies A Success Story Fastest growing segment of
More informationChallenges and Opportunities of Monoclonal Antibody Manufacturing in China
BioPharma Antibody Therapeutics News Digest Challenges and Opportunities of Monoclonal Antibody Manufacturing in China Chris Chen Introduction About the Author: Dr. Chris Chen is currently Chief Operating
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More informationProduction in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation
Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Industry Studies Association Pittsburgh, June 1, 2011 Elisabeth Reynolds, Ph.D.
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationMonoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.
Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided
More informationAccelerating drug development to FTIH: Potential of new expression technologies
Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum
More information"Small and large molecules bioproduction by mammalian and microbial fermentation"
"Small and large molecules bioproduction by mammalian and microbial fermentation" H.-P. Meyer Bio/PharMOS 2004-23-25 March 2004 Symposium B Business Diversification in Life Science "Small and large molecules
More informationImplementation of Advanced Chromatography techniques to Mitigate Purification Concerns in Bispecific Monoclonal Antibody Manufacturing
www.beroe- WHITEPAPER December 2012 inc.com Implementation of Advanced Chromatography techniques to Multi Column Solvent Gradient Purification or MCSGP chromatography process is a better solution to Bispecific
More informationIndustrialization of mab production technology The bioprocessing industry at a crossroads
REVIEW review 1:5, 443-452; September/October 2009; 2009 Landes Bioscience Industrialization of mab production technology The bioprocessing industry at a crossroads Brian Kelley Bioprocess Development;
More informationBiotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
More informationBiopharm Roundtable. 1. What, in your opinion, is currently the single largest trend with respect to biopharmaceutical outsourcing and manufacture?
BIOPHARM ROUNDTABLE Biopharm Roundtable Morrey Atkinson Vice President, R&D Cook Pharmica Peter Soelkner Managing Director Vetter Pharma-Fertigung GmbH & Co. KG Johannes Reiter Cooperations Manager Sandoz
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationTriskel: a strategic consulting firm for biopharmaceutical companies
BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationNext-Generation Facilities for Monoclonal Antibody Production
Advancing Development & Manufacturing Facilities Next-Generation Facilities for Monoclonal Antibody Production Niels Guldager ELECTRONICALLY REPRINTED FROM JULY 2009 The biopharmaceutical industry faces
More informationMultiple Products in a Monoclonal Antibody S88.01 Batch Plant
Presented at the World Batch Forum North American Conference Chicago, IL May 16-19, 2004 900 Fox Valley Drive, Suite 204 Longwood, FL 32779-2552 +1.407.774.0207 Fax: +1.407.774.6751 E-mail: info@wbf.org
More informationThe Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011
Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts
More informationFacility construction and start up for commercial scale manufacturing of monoclonal antibodies - A case study
24 th Interphex, Japan, Technical Conference June 29 th, 2011 Michael Brown Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - A case study Lonza AG Financially
More informationBIOTECH MANUFACTURING SOLUTIONS 4 YOUR SUCCESS. a Novartis company
a Novartis company BIOTECH MANUFACTURING Sandoz GmbH Biotech Cooperations 6250 Kundl Austria Biochemiestrasse10 Phone +43 (0)5338 200 2609 Fax +43 (0)5338 200 442 biotech.cooperations@sandoz.com www.sandoz.com
More informationIntroduction to Bioprocessing
Introduction to Bioprocessing Cambridge Healthtech Institute Peptalk Palm Springs, CA Presented by Susan Dana Jones and Sheila Magil BioProcess Technology Consultants www.bptc.com BioProcess Technology
More informationTransgenic technology in the production of therapeutic proteins
Transgenic technology in the production of therapeutic proteins Transgenic technology represents a new generation of biopharmaceutical production system to meet the medical needs of the new millennium.
More informationFlexibility in a Biotech Manufacturing Facility: An Options Analysis for Monoclonal Antibody Production
Flexibility in a Biotech Manufacturing Facility: An Options Analysis for Monoclonal Antibody Production ESD.71 Engineering Systems Analysis for Design Professor Richard de Neufville December 8, 2011 EXECUTIVE
More informationExciting Trends in Bioprocessing
Exciting Trends in Bioprocessing Alfred Doig and Susan Dana Jones, Ph.D. April 20, 2015 BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA 01801 Exciting Trends in Bioprocessing
More informationBiopharmaceutical Process Evaluated for Viral Clearance
Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate
More informationPlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
More informationAdvances in Biopharmaceutical and Vaccine Manufacturing Plants
Hitachi Review Vol. 62 (2013), No. 4 267 Advances in Biopharmaceutical and Vaccine Manufacturing Plants Sei Murakami, Dr. Eng. Haruo Suzuki Keisuke Shibuya, Dr. Sc. OVERVIEW: The development of innovative
More informationEfficient, Flexible Facilities for the 21st Century
F l e x-faci liti es disposables Efficient, Flexible Facilities for the 21st Century by Howard L. Levine, Jan E. Lilja, Rick Stock, Hans Hummel, Susan Dana Jones A number of recent improvements in the
More informationProcess-scale purification of monoclonal antibodies polishing using Capto Q
GE Healthcare Life Sciences Application note 28-937-16 AB Ion exchange chromatography Process-scale purification of monoclonal antibodies polishing using Capto Q Summary Anionic exchange media are an industry
More informationA new, integrated, continuous purification process template for monoclonal antibodies
A new, integrated, continuous purification process template for monoclonal antibodies Alex Xenopoulos* Alison Dupont, Christopher Gillespie, Ajish Potty, Michael Phillips Processing Technologies Merck
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More informationBioprocessing Media and Buffers Grow with Us
Bioprocessing Media and Buffers Grow with Us Experience Highly experienced media on the selection of standard media as well as development This service packaging, documentation Leading position in single-use
More informationAdvancements in Modularization
Advancements in Modularization Standardization, Modular Unit Operations and Global Deployment Interphex 2013 New York, NY Pär Almhem President ModWave & ModularPartners Outline Introduction to Modularization
More informationOutlook of China Biopharmaceutical Outsourcing Market
中 国 生 物 医 药 外 包 市 场 前 景 分 析 Outlook of China Biopharmaceutical Outsourcing Market JZMed, Inc. Report Description Attracted by the fast growth of the Chinese biopharmaceutical market as well as the thriving
More informationApplication Note. Separation of three monoclonal antibody variants using MCSGP. Summary
Application Note Separation of three monoclonal antibody variants using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, Biochromatography; FPLC Protein A-purified monoclonal
More informationOverview of Upstream and Downstream Processing of Biopharmaceuticals
Overview of Upstream and Downstream Processing of Biopharmaceuticals Ian Marison Professor of Bioprocess Engineering and Head of School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
More information4 th Annual Report and Survey of Biopharmaceutical Manufacturing, Capacity, and Production
4 th Annual Report and Survey of Biopharmaceutical Manufacturing, Capacity, and Production A Study of Biotherapeutic Developers and Contract Manufacturing Organizations 2006 BioPlan Associates, Inc. 15200
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationHigh yield antibody production in a disposable WAVE Bioreactor
High yield antibody production in a Process intensification using perfusion culture Christian Kaisermayer 1, Jianjun Yang 2 1 GE Healthcare Europe GmbH, Vienna, Austria (Christian.Kaisermayer@ge.com),
More informationDPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013.
DPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013 Page Safe harbor statement This presentation may contain forward-looking
More informationAdvanced Biopharmaceutical Manufacturing: An Evolution Underway
Life Sciences Advanced Biopharmaceutical Manufacturing: An Evolution Underway Executive summary The past decade has seen a significant shift in the nature of the products being manufactured and sold by
More informationProtein Synthesis and Purification: Microbial Versus Mammalian Systems
STREAMLINING RECOMBINANT PROTEIN PRODUCTION The pharmaceutical industry is undergoing a deep transformation from small molecule drugs to biologics. Over the last decade, the percentage share of biologic-based
More informationApplication Note. Increasing the activity of monoclonal antibody isoforms by MCSGP. Summary
Application Note Increasing the activity of monoclonal antibody isoforms by MCSGP Category Matrix Method Keywords Countercurrent chromatography, FPLC Antibodies MCSGP FPLC, Biobetters, MCSGP, countercurrent
More informationApplication Note. Purifying common light-chain bispecific antibodies using MCSGP. Summary
Application Note Purifying common light-chain bispecific antibodies using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, biochromatography Antibodies MCSGP Bispecific antibody,
More informationQbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins
QbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins 2015. 06. 09 Green Cross Corp. Green Cross Research Center Yong Jae Kim (YJKIM@greencross.com) Biologics World
More informationGlobal Monoclonal Antibodies Pipeline Insight 2015
Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who
More informationIP throughout the life cycle of Xencor a biotech company
IP throughout the life cycle of Xencor a biotech company Bassil Dahiyat Ph.D. President and CEO Proteins by Design Xencor snapshot Biopharmaceutical company with proprietary platform technologies 21 US
More informationBiologics: Specific Drug Safety Challenges. Violetta B. Kyburz
Biologics: Specific Drug Safety Challenges Violetta B. Kyburz 2012 2013 2014 Biologics: Specific Drug Safety Challenges Topics for discussion Particular issues in the preclinical development of biologics
More information(SAMPLE COPY, NOT FOR RESALE)
TriMark Publications June 2009 Volume: TMRTMA09-0601 THERAPEUTIC MONOCLONAL ANTIBODIES MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF
More informationPharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success
Pharmaceuticals Production Services Boehringer Ingelheim Our expertise in world-class contract manufacturing for your success Successful partnership Dr Wolfram Carius Head of Corporate Division Pharmaceuticals
More informationGuidance for Industry. Monoclonal Antibodies Used as Reagents in Drug Manufacturing
Guidance for Industry Monoclonal Antibodies Used as Reagents in Drug Manufacturing U.S. Department of Health and Human Services Food and Drug Administration enter for Drug Evaluation and Research (DER)
More informationBioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma
BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry
More informationHow single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs
WHITE PAPER 7004 How single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs By John Boehm Business Unit Manager Colder Products Company Today s
More informationManufacturer of drug substance
Original s and Biosimilars (marketing authorizations in the EU) Date: January 2016 1) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin
More informationBiopharmaceutical. Planning Pharmaceutical Manufacturing Strategies in an Uncertain World. William C. Brastow, Jr., and Craig W.
Planning Pharmaceutical Manufacturing Strategies in an Uncertain World William C. Brastow, Jr., and Craig W. Rice Biopharmaceutical manufacturers face one of the most uncertain planning environments in
More informationCompany Presentation June 2011 Biotest AG 0
Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and
More informationKMS-Specialist & Customized Biosimilar Service
KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal
More informationSimulation Why? Textmasterformate durch Klicken bearbeiten The planning of a biopharmaceutical facility requires the
Simulation Projects The planning of a biopharmaceutical facility requires the Simulation Why? consideration of various interdependent factors. A process simulation can help to optimise an existing process
More informationGlobal Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics
More informationSingle Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography
www.natrixseparations.com Complex Separations Single Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography AN1000 Summary Recombinant Shiga toxin
More informationPharmaceutical sales in Canada have a 2.5 percent share of the global market, making th
Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries
More informationPX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationGain efficiency in your process development with ÄKTA avant
Gain efficiency in your process development with ÄKTA avant gelifesciences.com Gain efficiency in your process development with ÄKTA avant Development of efficient manufacturing processes is a necessity
More informationTuas Biomedical Park
Tuas Biomedical Park About Tuas Biomedical Park Tuas Biomedical Park symbolises JTC s commitment in developing a world-class manufacturing hub for the biomedical industry. The park is located in Tuas View,
More informationOur passion is to deliver sustainable value to our customers 2007 First Half Results 26 July 2007
Our passion is to deliver sustainable value to our customers 2007 First Half Results 26 July 2007 Toralf Haag Chief Financial Officer Disclaimer Certain matters discussed in this presentation may constitute
More informationA Dynamic Simulation Framework for Biopharmaceutical Capacity Management
A Dynamic Simulation Framework for Biopharmaceutical Capacity Management A thesis submitted to University College London for the degree of DOCTOR OF ENGINEERING by Paige Ashouri, MEng The Advanced Centre
More informationHSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
More informationCommercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive
More informationPeptide purification strategies
Särö Conference 2009 Peptide purification strategies Ulf Altenhöner Lonza Exclusive Synthesis R&D Outline Introduction Integrated process development Model-based process development Inspiration Conclusions
More informationA Comparison of US and EU Biosimilars Regimes
A Comparison of US and EU Biosimilars Regimes summary statement Economic barriers, along with regulatory complexity and uncertainty, are shaping the biosimilars industry into something entirely different
More informationHighly Potent APIs The right platform, people and procedures for successful development and manufacturing
Pharma&Biotech Highly Potent APIs The right platform, people and procedures for successful development and manufacturing Custom Manufacturing and Development Services for Highly Potent APIs Pharma&Biotech
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationAdvances inthe Development. of Therapeutic
Advances inthe Development of Therapeutic Monoclonal Antibodies Susan Dana Jones, Francisco J. Castillo, Howard L. Levine ABSTRACT Monoclonal antibodies (MAbs) and related products are a dominant component
More informationChanges to an Approved Product
Changes to an Approved Product Chemistry, Manufacturing and Controls By Khandan Baradaran, PhD and Peggy Berry, MBA, RAC It is a huge achievement for any company to obtain licensing rights to an approved
More informationProcess Simulation and Modeling Strategies for the Biotechnology Industry
Process Simulation and Modeling Strategies for the Biotechnology Industry Optimizing Productivity in Multiproduct Batch Facilities Ian Gosling, Ph.D. www.chemsim.com Process simulation and modeling is
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationIn this second session of the CMC
B I O P R O C E S S TECHNICAL Defining Your Product Profile and Maintaining Control Over It, Part 2 Challenges of Monitoring Host Cell Protein Impurities Kathleen Champion, Helena Madden, John Dougherty,
More informationNational Student Design Competition 2010
National Student Design Competition 2010 If there are any questions about the Design Competition, student chapter advisors and design course instructors are asked to contact: Professor Richard L. Long
More informationMonoclonal antibodies
MAb Contaminant Removal with a Multimodal Anion Exchanger A Platform Step to Follow Protein A Kjell Eriksson, Anders Ljunglöf, Gustav Rodrigo, and Eggert Brekkan Reprinted with permission from BioProcess
More informationDr.ssa Maria Luisa Nolli CEO
IL RUOLO DELLE PICCOLE E MEDIE INDUSTRIE NELLA PROMOZIONE DELLA MEDICINA TRASLAZIONALE Quality and Innovation Dr.ssa Maria Luisa Nolli CEO INTRODUCTION ARETA INTERNATIONAL 12 years of experience in contract
More informationBiopharmaceutical Process Optimization with Simulation and Scheduling Tools
Bioengineering 2014, 1, 154-187; doi:10.3390/bioengineering1040154 OPEN ACCESS bioengineering ISSN 2306-5354 www.mdpi.com/journal/bioengineering Article Biopharmaceutical Process Optimization with Simulation
More informationStem Cells Market Trends based on Primary Industry Analysis
GENReports: Market & Tech Analysis Stem Cells Market Trends based on Primary Industry Analysis > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us > Gary Oosta,
More informationAnnual Press Conference 2012. Business Year 2011
Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation
More information